Elias Jabbour, MD
Pulmonary Disease · Warwick, RINPI 1598172082
Payments from drug & device makers
What this record shows
Intuitive Surgical accounts for 60.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $1,277 and has fallen 94.1% since, to $75 in 2025.
Across 45 payments — averaging $43.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- GSK$231
- Boehringer Ingelheim$172
- Sumitomo Pharma America, Inc.$116
- AstraZeneca$110
- Regeneron Healthcare Solutions, Inc.$40
- plus $110 from 5 others
Across 7 payments — averaging $1,880,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$13.2M
What the payments were for
- Travel & lodging$1,09556%
- Food & beverage$86344%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $1,179 |
| GSK | 13 | $231 |
| Boehringer Ingelheim | 8 | $172 |
| Sumitomo Pharma America, Inc. | 1 | $116 |
| AstraZeneca | 7 | $110 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Novartis | 2 | $33 |
| Merck | 1 | $30 |
| Verona Pharma, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,057
How this compares
$1,957 in reported general payments places this provider in the 65th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 56 | $720,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 860 | $626,837 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 181 | $130,763 |
| Dupixent PenDupilumab | 23 | $84,036 |
| Spiriva RespimatTiotropium Bromide | 126 | $75,182 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 123 | $69,794 |
| TezspireTezepelumab-Ekko | 11 | $50,553 |
| Incruse ElliptaUmeclidinium Bromide | 131 | $46,847 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $43,363 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $38,713 |
| EliquisApixaban | 30 | $19,362 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 73 | $18,078 |
| DuleraMometasone/Formoterol | 44 | $17,480 |
| Spiriva HandihalerTiotropium Bromide | 19 | $15,811 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $12,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $172 | $865,081305 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $231 | $765,3031,207 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $110 | $193,985231 claims |
| MerckDulera | $30 | $17,48044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Warwick
- William CorraoWarwick$166K
- Thomas RaimondoWarwick$8K
- Anuradha RamaswamyWarwick$3K
- Stephen MatareseWarwick$2K
- Khalid AlhouraniWarwick$2K
- Ashish ThakkarWarwick$1K
- Neil LaboveWarwick$350
- Gerald WeinhouseWarwick$15
- Michael StanchinaEast Greenwich$219K
- Corey VentetuoloRiverside$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.